Systemic lupus erythematosus
Two EULAR documents: the 2023 general SLE update and the 2025 update for SLE with kidney involvement, which replaces the nephritis recommendations of 2023 and the 2019 EULAR/ERA-EDTA guideline.
Clinical pearls
- Hydroxychloroquine for every patient, unless contraindicated, at ≤5 mg/kg/day.
- Steroids ≤5 mg/day prednisone for maintenance, and stop if possible.
- Biologics: belimumab (anti-BAFF) and anifrolumab (anti-type I interferon receptor) for active extrarenal disease; belimumab, voclosporin and obinutuzumab for nephritis.
- Lupus nephritis: biopsy at proteinuria ≥0.5 g/day; combination therapy first; continue ≥3 years.
- Thrombotic APS: warfarin.